Literature DB >> 6096399

Study of IgA in the cerebrospinal fluid of neurological patients with special reference to size, subclass and local production.

C J Sindic, D L Delacroix, J P Vaerman, E C Laterre, P L Masson.   

Abstract

IgA was assayed by particle counting immunoassay in cerebrospinal fluid (CSF) from non-neurological and neurological patients. Reference values had a logarithmic normal distribution with a mean of 1.54 mg/l and an upper limit of 5 mg/l. To estimate the possible intra-blood-brain barrier (BBB) production of IgA we have calculated an IgA index: CSF-IgA/serum-IgA: CSF-albumin/serum-albumin. Values higher than the upper reference limit of 0.41 were found in 12 out of 67 patients with multiple sclerosis (18%), in 5 out of 11 with aseptic meningitis, in 7 out of 8 with herpetic encephalitis, in 1 out of 8 with Guillain-Barré syndrome and in 2 cases of tuberculous meningitis. However, this index does not take into account the relative proportions of monomeric and polymeric IgA in CSF and serum. We therefore ultracentrifuged 17 paired CSF and serum samples and determined the relative proportions of monomeric and dimeric IgA and calculated the indices for monomeric and dimeric IgA. In controls the proportion of dimeric IgA in CSF was below 5% of total IgA whereas this proportion was increased up to 53.9% in the case of intra-BBB production of IgA, which is thus characterized by a very high dimeric IgA index. In all cases IgA1 remained the predominant subclass. These results had to be compared with those observed in cultures of peripheral blood lymphocytes, which secrete about equal proportions of monomeric and polymeric IgA pertaining to the IgA1 subclass.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6096399     DOI: 10.1016/s0165-5728(84)80007-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  A paraprotein IgA1 occurring in serum, urine, and cerebrospinal fluid (CSF): immunochemical and idiotypic evidence of synthesis in situ by the central nervous system (CNS).

Authors:  F Bollengier; A Mahler; A Gillard; E Wijffels
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

2.  Intrathecal production of specific IgA antibodies in CNS infections.

Authors:  M Roberg; P Forsberg; A Tegnell; K Ekerfeldt
Journal:  J Neurol       Date:  1995-06       Impact factor: 4.849

3.  Spinal arachnoiditis due to aspergillus meningitis in a previously healthy patient.

Authors:  F A Van de Wyngaert; C J Sindic; J J Rousseau; F G Fernandes Xavier; J M Brucher; E C Laterre
Journal:  J Neurol       Date:  1986-02       Impact factor: 4.849

Review 4.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

5.  Detection of oligoclonal IgA in cerebrospinal fluid samples by an isoelectric focusing procedure.

Authors:  W Withold; M Wick; A Fateh-Moghadam; K Einhäupl
Journal:  J Neurol       Date:  1994-03       Impact factor: 4.849

6.  Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.

Authors:  Addison E Stone; Sarah E Scheuermann; Colin N Haile; Gregory D Cuny; Marcela Lopez Velasquez; Joshua P Linhuber; Anantha L Duddupudi; Jennifer R Vigliaturo; Marco Pravetoni; Therese A Kosten; Thomas R Kosten; Elizabeth B Norton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

Review 7.  Know your enemy or find your friend?-Induction of IgA at mucosal surfaces.

Authors:  Mats Bemark; Davide Angeletti
Journal:  Immunol Rev       Date:  2021-07-30       Impact factor: 10.983

8.  Increased plasma and brain immunoglobulin A in Alzheimer's disease is lost in apolipoprotein E ε4 carriers.

Authors:  Dovilė Pocevičiūtė; Cristina Nuñez-Diaz; Bodil Roth; Shorena Janelidze; Andreas Giannisis; Oskar Hansson; Malin Wennström
Journal:  Alzheimers Res Ther       Date:  2022-08-26       Impact factor: 8.823

9.  Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.

Authors:  Ashley L St John; Hae Woong Choi; Q David Walker; Bruce Blough; Cynthia M Kuhn; Soman N Abraham; Herman F Staats
Journal:  NPJ Vaccines       Date:  2020-02-05       Impact factor: 7.344

10.  High prevalence of intrathecal IgA synthesis in multiple sclerosis patients.

Authors:  Úrsula Muñoz; Cristina Sebal; Esther Escudero; Maria Isabel García Sánchez; Elena Urcelay; Asier Jayo; Rafael Arroyo; Maria A García-Martínez; Roberto Álvarez-Lafuente; María C Sádaba
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.